Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AtriCure (ATRC) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for AtriCure (ATRC) over the last 17 years, with Q3 2025 value amounting to $151.6 million.

  • AtriCure's Total Non-Current Liabilities rose 183.28% to $151.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.6 million, marking a year-over-year increase of 183.28%. This contributed to the annual value of $147.1 million for FY2024, which is 42.24% up from last year.
  • As of Q3 2025, AtriCure's Total Non-Current Liabilities stood at $151.6 million, which was up 183.28% from $143.2 million recorded in Q2 2025.
  • AtriCure's Total Non-Current Liabilities' 5-year high stood at $151.6 million during Q3 2025, with a 5-year trough of $118.7 million in Q1 2021.
  • For the 5-year period, AtriCure's Total Non-Current Liabilities averaged around $133.6 million, with its median value being $130.5 million (2023).
  • Per our database at Business Quant, AtriCure's Total Non-Current Liabilities skyrocketed by 1741.19% in 2021 and then crashed by 220.05% in 2022.
  • AtriCure's Total Non-Current Liabilities (Quarter) stood at $130.3 million in 2021, then fell by 2.2% to $127.5 million in 2022, then rose by 14.95% to $146.5 million in 2023, then rose by 0.42% to $147.1 million in 2024, then grew by 3.01% to $151.6 million in 2025.
  • Its Total Non-Current Liabilities stands at $151.6 million for Q3 2025, versus $143.2 million for Q2 2025 and $135.8 million for Q1 2025.